Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Giulia GANZETTI 1, Anna CAMPANATI 1, Alberta BETTACCHI 2, Giuliano BRANDOZZI 1, Valerio BRISIGOTTI 1, Leonardo BUGATTI 3, Ivana CATALDI 1, Giorgio FILOSA 3, Alfredo GIACCHETTI 4, Giuseppe LEMME 1, Lorenzo MORRESI 5, Massimiliano NICOLINI 3, Valentina POSTACCHINI 1, Giuseppe RICOTTI 4, Laura ROSA 1, Marco SIMONACCI 2, Annamaria OFFIDANI 1
1 Dermatological Clinic, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy; 2 U.O.C. Dermatologia, Ospedale di Macerata, ASUR Marche AV3, Macerata, Italy; 3 U.O.C. Dermatologia, Ospedale “Carlo Urbani”, ASUR Marche AV2, Jesi, Ancona, Italy; 4 U.O.C. Dermatologia INRCA/IRCCS, Ancona, Italy; 5 U.O Dermatologia INRCA/IRCCS, Fermo, Italy
BACKGROUND: Switching is a “hot” topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient’s dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biological to another.
METHODS: Five Dermatological Units have participated to PsOMarche working group have studied thirty-eight patients affected moderate to severe chronic plaque psoriasis at time 0 (patient recruitment at time of switching from biological therapy to another), 8 weeks (T8), 16 weeks (T16).
RESULTS: 28 males and 10 females were included in the study. At T0, 18 of 22 patients treated with Etanercept had been switched to Adalimumab and 4 to Ustekinumab. Among 10 patients treated with Adalimumab, 5 had been switched to Ustekinumab, 2 to Golimumab and 3 to Certolizumab pegol. One patient treated with Infliximab and 5 patients treated with Ustekinumab had been switched to Adalimumab. Switching had been performed for primary inefficacy in 9 patients (23,6%) and a secondary failure was evidenced in 29 patients (73,4%). PASI75 was achieved in 53% and in 89.4% of patients after 8 weeks and 16 weeks of switching to the second biologic agent respectively; similarly, PSODISK score significantly decreased at T8 and T16
CONCLUSIONS: The experience of PsOMarche group have shown that the switching to a biologic agent to another is a valuable treatment choice in patients with moderate to severe psoriasis experiencing a treatment failure with one biologic therapy, leading to a good improvement in skin disease and in patient’s quality of life.